Celldex Therapeutics (NASDAQ:CLDX) Earns Neutral Rating from Analysts at The Goldman Sachs Group

Equities researchers at The Goldman Sachs Group initiated coverage on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research report issued on Monday, Marketbeat.com reports. The brokerage set a “neutral” rating and a $45.00 price target on the biopharmaceutical company’s stock. The Goldman Sachs Group’s target price indicates a potential upside of 38.89% from the stock’s current price.

Several other research firms also recently commented on CLDX. Stifel Nicolaus assumed coverage on shares of Celldex Therapeutics in a report on Tuesday, June 18th. They issued a “buy” rating and a $58.00 price objective for the company. Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 26th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a report on Monday, September 16th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Thursday, September 26th. Finally, Wolfe Research downgraded shares of Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.14.

Celldex Therapeutics Stock Down 4.7 %

Celldex Therapeutics stock opened at $32.40 on Monday. Celldex Therapeutics has a twelve month low of $22.11 and a twelve month high of $53.18. The firm has a 50 day moving average price of $38.30 and a 200-day moving average price of $38.18. The company has a market capitalization of $2.15 billion, a P/E ratio of -11.37 and a beta of 1.56.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. The firm had revenue of $2.50 million during the quarter, compared to the consensus estimate of $1.13 million. Equities analysts expect that Celldex Therapeutics will post -2.5 EPS for the current fiscal year.

Institutional Trading of Celldex Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Celldex Therapeutics during the 2nd quarter valued at $76,000. Headlands Technologies LLC purchased a new position in Celldex Therapeutics in the 1st quarter worth $147,000. CANADA LIFE ASSURANCE Co raised its position in Celldex Therapeutics by 26.4% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 955 shares during the period. Ameritas Investment Partners Inc. raised its position in Celldex Therapeutics by 34.3% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 1,582 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new position in Celldex Therapeutics in the 1st quarter worth $283,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.